ketoconazole has been researched along with Ischemia in 6 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight patients with recurrent ischemic priapism were treated with ketoconazole and prednisone." | 7.75 | Ketoconazole and prednisone to prevent recurrent ischemic priapism. ( Abern, MR; Levine, LA, 2009) |
| "Reperfusion after limb ischemia results in muscle edema as well as excess secretion of thromboxane A2 (TxA2), an agent associated with permeability increase in other settings." | 7.67 | Thromboxane A2 moderates permeability after limb ischemia. ( Alexander, F; Hechtman, HB; Lelcuk, S; Shepro, D; Valeri, CR, 1985) |
| " We compared our previous protocol of three times daily (TID) KTZ dosing with prednisone for 6 months with our current regimen of initiating KTZ 200 mg TID with prednisone 5 mg daily for 2 weeks and then tapering to KTZ 200 mg nightly for 6 months." | 5.40 | Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes. ( Hoeh, MP; Levine, LA, 2014) |
| "The ability of the imidazole derivative, ketoconazole, to inhibit thromboxane (Tx)A2 synthesis in response to ischemia was tested in ten volunteers." | 5.05 | Inhibition of ischemia-induced thromboxane synthesis in man. ( Hechtman, HB; Huval, WV; Lelcuk, S; Shepro, D; Valeri, CR, 1984) |
| "Eight patients with recurrent ischemic priapism were treated with ketoconazole and prednisone." | 3.75 | Ketoconazole and prednisone to prevent recurrent ischemic priapism. ( Abern, MR; Levine, LA, 2009) |
| "Reperfusion after limb ischemia results in muscle edema as well as excess secretion of thromboxane A2 (TxA2), an agent associated with permeability increase in other settings." | 3.67 | Thromboxane A2 moderates permeability after limb ischemia. ( Alexander, F; Hechtman, HB; Lelcuk, S; Shepro, D; Valeri, CR, 1985) |
| " We compared our previous protocol of three times daily (TID) KTZ dosing with prednisone for 6 months with our current regimen of initiating KTZ 200 mg TID with prednisone 5 mg daily for 2 weeks and then tapering to KTZ 200 mg nightly for 6 months." | 1.40 | Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes. ( Hoeh, MP; Levine, LA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Joice, GA | 1 |
| Liu, JL | 1 |
| Burnett, AL | 1 |
| Hoeh, MP | 1 |
| Levine, LA | 2 |
| Abern, MR | 1 |
| Lelcuk, S | 2 |
| Huval, WV | 1 |
| Valeri, CR | 2 |
| Shepro, D | 2 |
| Hechtman, HB | 2 |
| Proctor, KG | 1 |
| Shatkin, S | 1 |
| Kaminski, PM | 1 |
| Falck, JR | 1 |
| Capdevila, JH | 1 |
| Alexander, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study[NCT05142254] | Phase 2 | 64 participants (Actual) | Interventional | 2022-04-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ketoconazole and Ischemia
| Article | Year |
|---|---|
Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-Agonists; Algori | 2021 |
1 trial available for ketoconazole and Ischemia
| Article | Year |
|---|---|
Inhibition of ischemia-induced thromboxane synthesis in man.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Arm; Blood Platelets; Female; Humans; Ischemia; Ketoconazole; M | 1984 |
4 other studies available for ketoconazole and Ischemia
| Article | Year |
|---|---|
Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes.
Topics: 14-alpha Demethylase Inhibitors; Adolescent; Adult; Anemia, Sickle Cell; Clinical Protocols; Emergen | 2014 |
Ketoconazole and prednisone to prevent recurrent ischemic priapism.
Topics: Adult; Drug Dosage Calculations; Glucocorticoids; Humans; Ischemia; Ketoconazole; Male; Middle Aged; | 2009 |
Modulation of arteriolar blood flow by inhibitors of arachidonic acid oxidation after thermal injury: possible role for a novel class of vasodilator metabolites.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Arachidonic Acids; Arterioles | 1988 |
Thromboxane A2 moderates permeability after limb ischemia.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Capillary Permeability; Dogs; Extremities; Ischemia; Ketocona | 1985 |